S&P 500   3,321.75 (+0.03%)
DOW   29,186.27 (-0.03%)
QQQ   223.87 (+0.26%)
AAPL   317.70 (+0.36%)
FB   221.32 (-0.05%)
MSFT   165.70 (-0.48%)
GOOGL   1,484.17 (+0.13%)
AMZN   1,887.46 (-0.24%)
CGC   24.12 (-0.12%)
NVDA   250.05 (+0.85%)
BABA   222.37 (+0.05%)
MU   59.17 (+0.34%)
GE   11.37 (-2.49%)
TSLA   569.56 (+4.09%)
AMD   51.43 (+0.74%)
T   39.04 (+1.35%)
ACB   2.04 (+1.49%)
F   9.16 (-0.54%)
NFLX   326.00 (-3.58%)
PRI   126.65 (+0.19%)
BAC   34.36 (+0.29%)
DIS   144.01 (+0.31%)
GILD   63.43 (+1.28%)
S&P 500   3,321.75 (+0.03%)
DOW   29,186.27 (-0.03%)
QQQ   223.87 (+0.26%)
AAPL   317.70 (+0.36%)
FB   221.32 (-0.05%)
MSFT   165.70 (-0.48%)
GOOGL   1,484.17 (+0.13%)
AMZN   1,887.46 (-0.24%)
CGC   24.12 (-0.12%)
NVDA   250.05 (+0.85%)
BABA   222.37 (+0.05%)
MU   59.17 (+0.34%)
GE   11.37 (-2.49%)
TSLA   569.56 (+4.09%)
AMD   51.43 (+0.74%)
T   39.04 (+1.35%)
ACB   2.04 (+1.49%)
F   9.16 (-0.54%)
NFLX   326.00 (-3.58%)
PRI   126.65 (+0.19%)
BAC   34.36 (+0.29%)
DIS   144.01 (+0.31%)
GILD   63.43 (+1.28%)
S&P 500   3,321.75 (+0.03%)
DOW   29,186.27 (-0.03%)
QQQ   223.87 (+0.26%)
AAPL   317.70 (+0.36%)
FB   221.32 (-0.05%)
MSFT   165.70 (-0.48%)
GOOGL   1,484.17 (+0.13%)
AMZN   1,887.46 (-0.24%)
CGC   24.12 (-0.12%)
NVDA   250.05 (+0.85%)
BABA   222.37 (+0.05%)
MU   59.17 (+0.34%)
GE   11.37 (-2.49%)
TSLA   569.56 (+4.09%)
AMD   51.43 (+0.74%)
T   39.04 (+1.35%)
ACB   2.04 (+1.49%)
F   9.16 (-0.54%)
NFLX   326.00 (-3.58%)
PRI   126.65 (+0.19%)
BAC   34.36 (+0.29%)
DIS   144.01 (+0.31%)
GILD   63.43 (+1.28%)
S&P 500   3,321.75 (+0.03%)
DOW   29,186.27 (-0.03%)
QQQ   223.87 (+0.26%)
AAPL   317.70 (+0.36%)
FB   221.32 (-0.05%)
MSFT   165.70 (-0.48%)
GOOGL   1,484.17 (+0.13%)
AMZN   1,887.46 (-0.24%)
CGC   24.12 (-0.12%)
NVDA   250.05 (+0.85%)
BABA   222.37 (+0.05%)
MU   59.17 (+0.34%)
GE   11.37 (-2.49%)
TSLA   569.56 (+4.09%)
AMD   51.43 (+0.74%)
T   39.04 (+1.35%)
ACB   2.04 (+1.49%)
F   9.16 (-0.54%)
NFLX   326.00 (-3.58%)
PRI   126.65 (+0.19%)
BAC   34.36 (+0.29%)
DIS   144.01 (+0.31%)
GILD   63.43 (+1.28%)
Log in

NASDAQ:ORMP - Oramed Pharmaceuticals Stock Price, Forecast & News

$5.41
-0.06 (-1.10 %)
(As of 01/22/2020 04:00 PM ET)
Today's Range
$5.27
Now: $5.41
$5.55
50-Day Range
$4.58
MA: $5.14
$5.76
52-Week Range
$2.32
Now: $5.41
$6.05
Volume104,198 shs
Average Volume145,407 shs
Market Capitalization$95.95 million
P/E RatioN/A
Dividend YieldN/A
Beta1.42
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ORMP
CUSIPN/A
Phone844-967-2633

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.70 million
Cash Flow$0.83 per share
Book Value$0.97 per share

Profitability

Net Income$-14,350,000.00
Net Margins-297.30%

Miscellaneous

EmployeesN/A
Market Cap$95.95 million
Next Earnings Date4/8/2020 (Estimated)
OptionableOptionable

Receive ORMP News and Ratings via Email

Sign-up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter.


Oramed Pharmaceuticals (NASDAQ:ORMP) Frequently Asked Questions

What is Oramed Pharmaceuticals' stock symbol?

Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."

How were Oramed Pharmaceuticals' earnings last quarter?

Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) announced its quarterly earnings results on Thursday, January, 9th. The biotechnology company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.11. The biotechnology company had revenue of $0.67 million for the quarter. Oramed Pharmaceuticals had a negative net margin of 297.30% and a negative return on equity of 38.51%. View Oramed Pharmaceuticals' Earnings History.

When is Oramed Pharmaceuticals' next earnings date?

Oramed Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, April 8th 2020. View Earnings Estimates for Oramed Pharmaceuticals.

What price target have analysts set for ORMP?

2 brokers have issued 12 month target prices for Oramed Pharmaceuticals' stock. Their forecasts range from $7.00 to $20.00. On average, they anticipate Oramed Pharmaceuticals' share price to reach $13.50 in the next twelve months. This suggests a possible upside of 149.5% from the stock's current price. View Analyst Price Targets for Oramed Pharmaceuticals.

What is the consensus analysts' recommendation for Oramed Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oramed Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oramed Pharmaceuticals.

Has Oramed Pharmaceuticals been receiving favorable news coverage?

Media coverage about ORMP stock has trended neutral this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Oramed Pharmaceuticals earned a media sentiment score of 0.5 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an effect on the stock's share price in the near term. View News Stories for Oramed Pharmaceuticals.

Are investors shorting Oramed Pharmaceuticals?

Oramed Pharmaceuticals saw a decline in short interest in December. As of December 31st, there was short interest totalling 448,700 shares, a decline of 23.5% from the December 15th total of 586,300 shares. Based on an average daily volume of 210,900 shares, the days-to-cover ratio is currently 2.1 days. Currently, 3.4% of the shares of the company are short sold. View Oramed Pharmaceuticals' Current Options Chain.

Who are some of Oramed Pharmaceuticals' key competitors?

What other stocks do shareholders of Oramed Pharmaceuticals own?

Who are Oramed Pharmaceuticals' key executives?

Oramed Pharmaceuticals' management team includes the folowing people:
  • Mr. Nadav Kidron, CEO, Pres & Exec. Director (Age 45)
  • Dr. Miriam Kidron, Chief Scientific Officer, Chief Medical & Technology Officer and Director (Age 79)
  • Ms. Hilla Eisenberg CPA, CFO, Treasurer & Sec. (Age 35)
  • Dr. Roy Eldor M.D., Ph.D., Chief Medical Advisor & Member of the Scientific Advisory Board

How do I buy shares of Oramed Pharmaceuticals?

Shares of ORMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Oramed Pharmaceuticals' stock price today?

One share of ORMP stock can currently be purchased for approximately $5.41.

How big of a company is Oramed Pharmaceuticals?

Oramed Pharmaceuticals has a market capitalization of $95.95 million and generates $2.70 million in revenue each year. The biotechnology company earns $-14,350,000.00 in net income (profit) each year or $0.82 on an earnings per share basis. View Additional Information About Oramed Pharmaceuticals.

What is Oramed Pharmaceuticals' official website?

The official website for Oramed Pharmaceuticals is http://www.oramed.com/.

How can I contact Oramed Pharmaceuticals?

Oramed Pharmaceuticals' mailing address is 1185 AVENUE SUITE 228, NEW YORK NY, 10036. The biotechnology company can be reached via phone at 844-967-2633 or via email at [email protected]


MarketBeat Community Rating for Oramed Pharmaceuticals (NASDAQ ORMP)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  278 (Vote Outperform)
Underperform Votes:  165 (Vote Underperform)
Total Votes:  443
MarketBeat's community ratings are surveys of what our community members think about Oramed Pharmaceuticals and other stocks. Vote "Outperform" if you believe ORMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ORMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/22/2020 by MarketBeat.com Staff

Featured Article: Cryptocurrencies

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel